UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 8, 2006
MGI PHARMA, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| Minnesota | | 0-10736 | | 41-1364647 |
| | | | | |
(State or other jurisdiction of
incorporation or organization) | | (Commission File
Number) | | (I.R.S. Employer
Identification No.) |
| | | |
| 5775 West Old Shakopee Road, Suite 100, Bloomington, Minnesota | | 55437 |
| | | |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (952) 346-4700
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
INFORMATION TO BE INCLUDED IN THE REPORT
Section 7 — Regulation FD
Item 7.01. Regulation FD Disclosure
On August 8, 2006, MGI PHARMA, INC. (the “Company”) completed the sale to Medicure Inc. of the Company’s rights to AGGRASTAT® Injection (tirofiban hydrochloride). The Company had originally acquired rights to the product through its acquisition of Guilford Pharmaceuticals Inc.
As a result of the sale, the Company will receive net proceeds of approximately $17 million. The Company is also expected to provide certain transition services to Medicure Inc. through at least February 4, 2007.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | |
| | | MGI PHARMA, INC. | | |
| | | | | | | |
| Date: August 11, 2006 | | By: | | /s/ William F. Spengler | | |
| | | | | William F. Spengler | | |
| | | | | Senior Vice President and | | |
| | | | | Chief Financial Officer | | |
3
